Scoop: SR One crew com­pletes a com­pli­cat­ed spin­out from Glax­o­SmithK­line. And now they have a $500M fund to in­vest on their own

It’s tak­en close to 2 years, but Sime­on George and his team at SR One have com­plet­ed their spin­out from Glax­o­SmithK­line, end­ing a saga as one of the longest run­ning ven­ture arms of Big Phar­ma as they go out on their own to forge the next chap­ter with a new and in­de­pen­dent $500 mil­lion fund.

GSK is stick­ing with the spin­out, this time as a mi­nor­i­ty in­vestor — though a big one. And I’m told that the R&D group at GSK will re­main in­volved in eval­u­at­ing their new plays, help­ing with the sci­en­tif­ic due dili­gence in­volved in scout­ing the world for new op­por­tu­ni­ties dur­ing a pe­ri­od of ex­plo­sive growth in biotech in­vest­ing.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER